Print Friendly, PDF & Email

Lysophosphatidic Acid Receptor 3 CT (EDG-7)

Catalogue number: X1227B

Blocking peptide for use in Western blotting with Anti-EDG7 (LPA3) (CT) (Cat. No. X1183P)

Product Type Blocking Peptide
Units50 µg
Application Antibody function blocking
Product Form

Endothelial Cell Differentiation Gene-7 (EDG7) (LPA3) belongs to a family of G-protein coupled receptors whose ligands are lysophospholipids. The ligand for EDG-7 is lysophospholipid. There are 8 known members of the EDG receptor family and they are implicated in mediating growth related effects such as induction of cellular proliferation, alterations in differentiation and survival and suppression of apoptosis. They also evoke cellular effector functions that are dependent on cytoskeletal responses such as contraction, secretion, adhesion and chemotaxis. EDG receptors are developmentally regulated and differ in tissue distribution. They couple to multiple types of G proteins to signal through ras and MAP kinase, rho, phospholipase C and several protein tyrosine kinases. EDG7 (LPA3) is expressed in prostate as well as other tissues.

See vial for concentration

Provided in solution at 1 mg/ml in phosphate buffered saline.

Functional Analysis
Western Blotting

For use with EDG7 (LPA3) (CT) polyclonal antibody (Cat. No. X1183P).

Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles

Ship Conditions
Ship at ambient temperature, freeze upon arrival

Product Stability
Products are stable for one year from purchase when stored properly

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.

Safety Datasheet(s) for this product:

Lysophosphatidic Acid Receptor 3 CT (EDG-7)



Contact us

Exalpha Biologicals, Inc.
2 Shaker Road, Unit B101
Shirley, MA 01464
Phone: 978-425-1370